You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor T-Cell (CART-T) therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Leukemia, Lymphoma, Cardiotoxicity Trial in Philadelphia

Completed
  • Leukemia
  • +4 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 19, 2023

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

    Active, not recruiting
    • Non-Hodgkin's Lymphoma
    • Hodgkin's Lymphoma
    • CAR.CD30 T cells
    • Chapel Hill, North Carolina
    • +2 more
    Mar 16, 2022

    CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

    Not yet recruiting
    • Lymphoma
    • Chimeric Antigen Receptor
    • (no location specified)
    Oct 24, 2023

    Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

    Not yet recruiting
    • Recurrent Multiple Myeloma
    • Refractory Multiple Myeloma
    • Bone Marrow Aspiration
    • +10 more
    • Los Angeles, California
      Melanie Ayala Ceja
    Jul 10, 2023

    Relapsed/Refractory Multiple Myeloma(MM) Trial in Guangdong (CART therapy in Relapsed/Refractory multiple myeloma)

    Terminated
    • Relapsed/Refractory Multiple Myeloma(MM)
    • CART therapy in Relapsed/Refractory multiple myeloma
    • Guangdong, Guangdong, China
      Southern Medical University Zhujiang Hospital
    Sep 17, 2021

    Solid Tumor Trial (HER2-E-CART cells)

    Not yet recruiting
    • Solid Tumor
    • HER2-E-CART cells
    • (no location specified)
    Feb 16, 2023

    ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Jun 7, 2021

      T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

      Not yet recruiting
      • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
      • CD7-CART01
      • (no location specified)
      Sep 26, 2023

      SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

      Not yet recruiting
      • SLE (Systemic Lupus)
      • CAR T-cell therapy
      • Bangkok, Please Select, Thailand
        King Chulalongkorn Memorial Hospital
      Nov 23, 2023

      Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

      Not yet recruiting
      • Multiple Sclerosis
      • +2 more
      • KYV-101 anti-CD19 CAR-T cell therapy
      • Standard lymphodepletion regimen
      • Palo Alto, California
        Stanford Multiple Sclerosis Center
      Nov 13, 2023

      Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

      Recruiting
      • Lupus Nephritis
      • +2 more
      • KYV-101 anti-CD19 CAR-T cell therapy
      • Standard lymphodepletion regimen
      • Denver, Colorado
      • +1 more
      Jul 7, 2023

      Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

      Recruiting
      • Lymphoblastic Leukemia
      • +4 more
      • Phase I
      • Phase II
      • Singapore, Singapore
        KK Women's and Children's hospital
      Jun 20, 2022

      Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)

      Unknown status
      • Leukemia
      • Lymphoma
      • Anti-CD22-CAR-transduced T cells
      • Beijing, Beijing, China
        Fengtai District
      Feb 6, 2021

      Acute Myeloid Leukemia Trial in Suzhou (anti-CLL1 CART)

      Recruiting
      • Acute Myeloid Leukemia
      • anti-CLL1 CART
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      May 10, 2021

      B-All, Acute Lymphoblastic Leukemia Trial run by the National Cancer Institute (NCI) (NGS testing)

      Not yet recruiting
      • B-All
      • Acute Lymphoblastic Leukemia
      • NGS testing
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 2, 2023

      Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

      Recruiting
      • Acute Myeloid Leukemia
      • Anti-CLL1 CART cells
      • Kunming, Yunnan, China
        No.212 Daguan Road, Xishan District
      Nov 23, 2022

      Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

      Not yet recruiting
      • Neuroendocrine Tumor (NET)
      • Colorectal Cancer (CRC)
      • CHM-2101 CAR-T cells
      • (no location specified)
      Sep 20, 2023

      Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

      Recruiting
      • Hairy Cell Leukemia
      • Hairy Cell Leukemia Variant
      • CD22CART cell infusion
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 25, 2023

      Digestive Tumor Trial (TM4SF1-positive chimeric antigen receptor T-cell therapy)

      Not yet recruiting
      • Digestive Tumor
      • TM4SF1-positive chimeric antigen receptor T-cell therapy
      • (no location specified)
      Dec 21, 2022

      Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

      Not yet recruiting
      • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
      • Zhengzhou, Henan, China
        Henan cancer hospital
      Nov 28, 2022

      Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)

      Not yet recruiting
      • Lymphoma
      • +2 more
      • Web Application
      • San Francisco, California
        University of California, San Francisco
      Oct 4, 2022

      19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

      Recruiting
      • 19 and 22+ B Cell Hematologic Tumors
      • 19 and 20+ B Cell Hematologic Tumors
      • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
      • Wuhan, Hubei, China
        Tongji Hospital
      Jan 11, 2023

      Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

      Unknown status
      • Relapsed Non Hodgkin Lymphoma
      • Refractory Non-Hodgkin Lymphoma
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Jul 30, 2021